A5002008877- Atrial Fibrillation Management and Outcomes
- Diabetes and associated disorders
- Diabetes Management and Research
- Acute Ischemic Stroke Management
- Venous Thromboembolism Diagnosis and Management
- Pancreatic function and diabetes
- Intracerebral and Subarachnoid Hemorrhage Research
- Health Systems, Economic Evaluations, Quality of Life
- Immune Cell Function and Interaction
- Colorectal Cancer Surgical Treatments
- Carbohydrate Chemistry and Synthesis
- Antiplatelet Therapy and Cardiovascular Diseases
- Advancements in Transdermal Drug Delivery
- Biochemical Analysis and Sensing Techniques
- RNA and protein synthesis mechanisms
- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- T-cell and B-cell Immunology
- Colorectal and Anal Carcinomas
- Aortic aneurysm repair treatments
- Gastric Cancer Management and Outcomes
Swansea University
2016-2025
University College London
1988
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay loss of β-cells but needs to have minimal adverse effects be an adjunct insulin management T1D. Ustekinumab binds shared p40 subunit interleukin (IL)-12 and IL-23, development T helper cells 17 (T
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known its positive safety profile) was conjugated ultrasmall gold nanoparticles (GNPs), attractive drug delivery platform due the potential anti-inflammatory properties of gold....
Background Type 1 diabetes is an autoimmune disease affecting over 400,000 children and adults in the United Kingdom for which currently only available therapy insulin. Objective(s) To determine efficacy safety of monoclonal antibody ustekinumab targeting interleukin 12/interleukin 23 immune pathway that generates T helper 1/T 17 cells to slow down process preserve beta cell production type diabetes. Design Randomised, double-blind, placebo-controlled, parallel-group phase II trial. Setting...
Summary Glycine tastes both bitter and sweet to mice but there are differences between strains in their ability detect each taste. With respect the taste, fifteen were classified as tasters twelve non-tasters. The difference is due a single gene, Glb (glycine bitterness). Cycloheximide all at concentration of 8 μM, strain sensitivity taste cycloheximide can be detected lower concentrations. BXD RI into two groups with cycloheximide. This probably segregation alleles Cyx . A comparison...
Introduction Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%–20% of beta-cell function remaining at the time diagnosis. Preservation residual diagnosis may improve glycaemic control and reduce longer-term complications. Immunotherapy has potential to preserve endogenous thereby metabolic even in poorly compliant individuals. We propose test ustekinumab (STELARA), a targeted well-tolerated therapy that halt T-cell cytokine-mediated destruction beta-cells pancreas Methods...
Introduction There are 11 500 rectal cancers diagnosed annually in the UK. Although surgery remains primary treatment, there is evidence that preoperative radiotherapy (RT) improves local recurrence rates. High-quality cancer equally important minimising recurrence. Advances MRI-guided prediction of resection margin status and improvements abdominoperineal excision rectum (APER) technique supports a reassessment contribution RT. A more selective approach to RT may be appropriate given...
Objective To evaluate the feasibility of recruiting participants diagnosed with atrial fibrillation (AF) taking oral anticoagulation therapies (OATs) and recently experiencing a bleed to collect health-related quality life (HRQoL) information. Design Observational study. The study aimed determine minor major bleeds, most appropriate route for recruitment appropriateness patient-reported outcome measures (PROMs) selected collecting HRQoL information in AF patients, preferred format surveys....
Abstract Background Oral anticoagulation therapies (OATs) are often prescribed in conjunction with medications to restore normal heart rate rhythm which can limit the risk of an atrial fibrillation (AF) related stroke and systemic thromboembolism. However, they associated serious side effect bleeding. Both clinically relevant nonmajor bleeding (CRNMB) major while anticoagulated believed have a significant impact on patient quality life (QoL). There is currently limited research into has QoL....
Abstract Background Atrial fibrillation (AF) is the most common cardiac arrhythmia. Oral anticoagulation therapies (OATs) are often prescribed in conjunction with medications to restore normal heart rate rhythm which can limit risk of an AF-related stroke and systemic thromboembolism. However, they associated serious side effect bleeding. Both clinically relevant non-major bleeding (CRNMB) major while anticoagulated believed have a significant impact on patient quality life (QoL). There...